Essential Thrombocythemia · line 1 · Hydroxyurea (PV / ET high-risk 1L cytoreduction) + baseline phlebotomy/ASA
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-HU-PV-ET |
| ID | IND-ET-1L-HU |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-ET |
| Sources | SRC-ESMO-MPN-2015 SRC-NCCN-MPN-2025 |
Notes
AGGRESSIVE track for ET 1L high-risk. STUB — requires clinical co-lead signoff.
Used By
Algorithms
ALGO-ET-1L- ALGO-ET-1L